U.S. Bioscience regulatory update

NeuTrexin received clearance in the U.K., Spain, the Netherlands, and Luxembourg for use in conjunction with leucovorin as an alternative therapy for moderate-to-severe PCP in patients with AIDS who are intolerant of, or refractory to standard therapy, or for whom standard therapy is contraindicated. UBS said it is in discussions with potential European marketing partners for NeuTrexin.

Separately, UBS said it trimmed its staff to 112 employees from 165. The West Conshohocken, Penn., company, which has $24 million in cash, was burning $5-6 million per quarter prior to the cuts. The company declined to discuss its burn going forward. ...